Suarez, Jose I. http://orcid.org/0000-0003-0548-9936
,
Sheikh, Muniza K.
Macdonald, R. Loch
Amin-Hanjani, Sepideh
Brown, Robert D. Jr.
de Oliveira Manoel, Airton Leonardo
Derdeyn, Colin P.
Etminan, Nima
Keller, Emanuela
Leroux, Peter D.
Mayer, Stephan A.
Morita, Akio
Rinkel, Gabriel
Rufennacht, Daniel
Stienen, Martin N.
Torner, James
Vergouwen, Mervyn D. I.
Wong, George K. C.
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (HHSN271201200034C)
Neurocritical Care Society
CHI Baylor St Luke's Medical Center
Article History
First Online: 13 May 2019
Compliance with Ethical Standards
:
: Logistical support for this project was provided in part through NIH Contract HHSN271201200034C, the Intramural Research Program of the NIH, NLM, The Neurocritical Care Society and the CHI Baylor St Luke’s Medical Center in Houston, TX.
: Dr Suarez reports being President of the Neurocritical Care Society, a member of the Editorial Board of Stroke Journal, and Chair of the DSMB for the INTREPID Study sponsored by BARD, outside of the submitted work. Dr Mayer reports having received personal consulting fees from Edge Therapeutics and Idorsia Pharmaceuticals outside of the submitted work. Dr Macdonald reports personal fees from Edge Therapeutics, and grants from Brain Aneurysm Foundation, outside the submitted work. Dr Amin-Hanjani, has nothing to disclose. Dr Stienen reports grants from Fujirebio Europe, and Actelion/Idorsia, outside of the submitted work. Dr Keller, Dr Vergouwen, Dr LeRoux, Dr Morita, Dr Brown, Dr Torner, Dr Rinkel, Dr Wong, Dr Rufennacht, Dr LeRoux, Dr de Oliveira Manoel, Ms Sheikh: has nothing to disclose.
: This project did not involve patient contact or review of patient-related information and thus it was not considered human research.